M. N. Skryabina

M. N. Skryabina

Auto-generated profile, based on publicly available information

M. N. Skryabina

Lomonosov Moscow State University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
APAlexandra Leonidovna Primak
Alexandra Leonidovna Primak
MSM.N. Skryabina
M.N. Skryabina
SDS.S. Dzhauari
S.S. Dzhauari
Vsevolod A. TkachukVsevolod A. Tkachuk
Vsevolod A. Tkachuk
MKMaxim Karagyaur
Maxim Karagyaur
Ischemic and hemorrhagic strokes, traumatic brain injury, bacterial and viral encephalitis, toxic and metabolic encephalopathies are very different pathologies. But, they have much more in common than it might seem at first glance. In this review, the authors propose to consider these brain pathologies from the point of view of the unity of their pathogenetic mechanisms and approaches to therapy. Particular attention is paid to promising therapeutic approaches, such as therapy using cells and their secretion products: an analysis of the accumulated experimental data, the advantages and limitations of these approaches in the treatment of brain damage was carried out. The review may be of interest both to specialists in the field of neurology, neurosurgery and neurorehabilitation, and to readers who want to learn more about the progress of regenerative biomedicine in the treatment of brain pathologies.

6 July 2022 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
SDS. S. Dzhauari
S. S. Dzhauari
MKMaxim Karagyaur
Maxim Karagyaur
VBV. Yu. Balabanyan
V. Yu. Balabanyan
MSM. N. Skryabina
M. N. Skryabina
APAlexandra Leonidovna Primak
Alexandra Leonidovna Primak
ВБВ. Ю. Балабаньян
В. Ю. Балабаньян
Relevance. The use of gene therapy drugs for the treatment of genetic diseases and stimulation of regeneration processes is lengthy and involves repeated injections, which may lead to increased dissemination of gene therapy constructs from the injection site and undesirable ectopic expression of growth factors encoded in them. Existing approaches to study the pharmacokinetics of a drug to assess the dissemination of a gene therapy drug from the site of administration are not applicable. Objective: to evaluate the suitability of the real-time PCR method for studying the biodistribution of a promising gene therapy drug in mice during a course of use. Methods. Male F1 CBA×C57/Black mice after nerve injury were injected with the test plasmid into the denervated tibial muscle after nerve injury, as well as after 4, 9 and 13 days at a dosage of 60 and 120 μg/mouse. After 7, 14, and 28 days, organ and tissue samples were removed, total DNA was isolated, and plasmid DNA content was assessed by real-time PCR. Results. We have shown that the studied genetic construct is able to disseminate from the injection site. We have found that the peak of dissemination for this construct in the organs and tissues of the mouse is reached 14–28 days after the end of the course application, while ectopic expression of growth factors is not observed in them. Conclusion. The proposed method is specific, highly sensitive, and linear over a wide range of concentrations. Thus, it can be recommended for studying the biodistribution of potential gene therapy drugs in the body of experimental animals as part of a preclinical studies complex.